These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 8543979

  • 21. Marked reduction of striatal dopamine D2 receptors as detected by 123IBZM-SPECT in a Wilson's disease patient with generalized dystonia.
    Schwarz J, Tatsch K, Vogl T, Kirsch CM, Trenkwalder C, Arnold G, Gasser T, Oertel WH.
    Mov Disord; 1992; 7(1):58-61. PubMed ID: 1532631
    [Abstract] [Full Text] [Related]

  • 22. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
    Dresel S, Mager T, Rossmüller B, Meisenzahl E, Hahn K, Möller HJ, Tatsch K.
    Eur J Nucl Med; 1999 Aug; 26(8):862-8. PubMed ID: 10436199
    [Abstract] [Full Text] [Related]

  • 23. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.
    Frankle WG, Gil R, Hackett E, Mawlawi O, Zea-Ponce Y, Zhu Z, Kochan LD, Cangiano C, Slifstein M, Gorman JM, Laruelle M, Abi-Dargham A.
    Psychopharmacology (Berl); 2004 Oct; 175(4):473-80. PubMed ID: 15083259
    [Abstract] [Full Text] [Related]

  • 24. In vitro and in vivo D2-dopamine receptor binding with [123I]S(-) iodobenzamide ([123I]IBZM) in rat and human brain.
    Verhoeff NP, Bobeldijk M, Feenstra MG, Boer GJ, Maas MA, Erdtsieck-Ernste E, de Bruin K, van Royen EA.
    Int J Rad Appl Instrum B; 1991 Oct; 18(8):837-46. PubMed ID: 1839302
    [Abstract] [Full Text] [Related]

  • 25. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
    Bernardo M, Parellada E, Lomeña F, Catafau AM, Font M, Gómez JC, López-Carrero C, Gutiérrez F, Pavía J, Salamero M.
    Psychiatry Res; 2001 Aug 25; 107(2):87-97. PubMed ID: 11530275
    [Abstract] [Full Text] [Related]

  • 26. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.
    Jauss M, Krack P, Franz M, Klett R, Bauer R, Gallhofer B, Dorndorf W.
    Mov Disord; 1996 Nov 25; 11(6):726-8. PubMed ID: 8914102
    [Abstract] [Full Text] [Related]

  • 27. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
    Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, Gonzales R, Kim JH, Alvarez B, Gil R, Laruelle M, Abi-Dargham A.
    Neuropsychopharmacology; 2008 Dec 25; 33(13):3111-25. PubMed ID: 18418366
    [Abstract] [Full Text] [Related]

  • 28. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.
    Lavalaye J, Linszen DH, Booij J, Reneman L, Gersons BP, van Royen EA.
    Psychiatry Res; 1999 Nov 08; 92(1):33-44. PubMed ID: 10688158
    [Abstract] [Full Text] [Related]

  • 29. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide.
    Abi-Dargham A, Kegeles LS, Zea-Ponce Y, Mawlawi O, Martinez D, Mitropoulou V, O'Flynn K, Koenigsberg HW, Van Heertum R, Cooper T, Laruelle M, Siever LJ.
    Biol Psychiatry; 2004 May 15; 55(10):1001-6. PubMed ID: 15121484
    [Abstract] [Full Text] [Related]

  • 30. Dynamic SPECT imaging of dopamine D2 receptors in human subjects with iodine-123-IBZM.
    Seibyl JP, Woods SW, Zoghbi SS, Baldwin RM, Dey HM, Goddard AW, Zea-Ponce Y, Zubal G, Germine M, Smith EO.
    J Nucl Med; 1992 Nov 15; 33(11):1964-71. PubMed ID: 1432157
    [Abstract] [Full Text] [Related]

  • 31. Dopamine D2 receptor imaging with iodine-123-iodobenzamide SPECT in idiopathic rotational torticollis.
    Hierholzer J, Cordes M, Schelosky L, Richter W, Keske U, Venz S, Semmler W, Poewe W, Felix R.
    J Nucl Med; 1994 Dec 15; 35(12):1921-7. PubMed ID: 7989970
    [Abstract] [Full Text] [Related]

  • 32. Test-retest variability and reliability of 123I-IBZM SPECT measurement of striatal dopamine D2 receptor availability in healthy volunteers and influence of iterative reconstruction algorithms.
    Catafau AM, Bullich S, Danús M, Penengo MM, Cot A, Abanades S, Farré M, Pavía J, Ros D.
    Synapse; 2008 Jan 15; 62(1):62-9. PubMed ID: 17960766
    [Abstract] [Full Text] [Related]

  • 33. Graphical analysis and simplified quantification of striatal and extrastriatal dopamine D2 receptor binding with [123I]epidepride SPECT.
    Ichise M, Fujita M, Seibyl JP, Verhoeff NP, Baldwin RM, Zoghbi SS, Rajeevan N, Charney DS, Innis RB.
    J Nucl Med; 1999 Nov 15; 40(11):1902-12. PubMed ID: 10565788
    [Abstract] [Full Text] [Related]

  • 34. Initial experience with SPECT examinations using [123I]IBZM as a D2-dopamine receptor antagonist in Parkinson's disease.
    Cordes M, Henkes H, Laudahn D, Bräu H, Kramp W, Girke W, Hierholzer J, Eichstädt H, Felix R.
    Eur J Radiol; 1991 Nov 15; 12(3):182-6. PubMed ID: 1830273
    [Abstract] [Full Text] [Related]

  • 35. Comparison of intravenous and intraperitoneal [123I]IBZM injection for dopamine D2 receptor imaging in mice.
    Meyer PT, Salber D, Schiefer J, Cremer M, Schaefer WM, Kosinski CM, Langen KJ.
    Nucl Med Biol; 2008 Jul 15; 35(5):543-8. PubMed ID: 18589298
    [Abstract] [Full Text] [Related]

  • 36. Striatal dopamine release after prefrontal repetitive transcranial magnetic stimulation in major depression: preliminary results of a dynamic [123I] IBZM SPECT study.
    Pogarell O, Koch W, Pöpperl G, Tatsch K, Jakob F, Zwanzger P, Mulert C, Rupprecht R, Möller HJ, Hegerl U, Padberg F.
    J Psychiatr Res; 2006 Jun 15; 40(4):307-14. PubMed ID: 16259998
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Stability of [123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans.
    Kegeles LS, Zea-Ponce Y, Abi-Dargham A, Rodenhiser J, Wang T, Weiss R, Van Heertum RL, Mann JJ, Laruelle M.
    Synapse; 1999 Mar 15; 31(4):302-8. PubMed ID: 10051112
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.